Physicians' Academy for Cardiovascular Education

Safety of NOAC instead of aspirin in ACS patients

Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial

Presented at ACC.17 by Magnus E Ohman

News - Mar. 18, 2017

Main results

Conclusion

A safety study of rivaroxaban versus aspirin, on top of P2Y12 therapy in ACS patients, showed that this dual antithrombotic regimen had a similar risk of clinically significant bleeding. These findings suggest that substituting aspirin with low-dose rivaroxaban is a safe therapeutic option in this setting.

Disclosures

Our coverage of ACC.17 is based on the information provided during the congress.

The accompanying article was published today in The Lancet

Share this page with your colleagues and friends: